Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical activity and safety of two doses of
VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.